

CHOLESTECH CORPORATION

Form 8-K

April 21, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) April 21, 2004

---

**CHOLESTECH CORPORATION**

---

(Exact name of registrant as specified in its charter)

California

---

000-20198

---

94-3065493

---

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3347 Investment Boulevard, Hayward, California

---

94545

---

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (510) 732-7200

---

Not applicable

---

(Former name or former address, if changed since last report)

---

**TABLE OF CONTENTS**

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 12 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

SIGNATURES

Index to Exhibits

EXHIBIT 99.1

---

**Table of Contents**

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Cholestech Corporation dated April 21, 2004

**ITEM 12 RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

On April 21, 2004, Cholestech Corporation ( Cholestech ) is issuing a press release and holding a conference call regarding its financial results for the fiscal year ended March 26, 2004. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

**Use of Non-GAAP Financial Measures**

To supplement its consolidated financial statements presented in accordance with GAAP, Cholestech uses a non-GAAP measure, operating income from continuing operations, which is adjusted from results based on GAAP to exclude legal and related expenses incurred in connection with the settlement of certain litigation and a write-off of intangibles. Further details about these charges can be found in the reconciliation included in the press release.

Operating income (loss) from continuing operations, excluding special items, is provided to enhance investors overall understanding of Cholestech s operational performance, current financial performance and its prospects for the future. Specifically, Cholestech believes this non-GAAP financial measure provides useful information to both management and investors by excluding certain special items that Cholestech believes is not indicative of its core operating results. In addition, since Cholestech has reported similar non-GAAP information to the investment community in the past, Cholestech believes the inclusion of the non-GAAP financial measure provides consistency in its financial reporting. Further, non-GAAP information allows for greater transparency to supplemental information used by management in its financial and operational decision making. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States. The non-GAAP information Cholestech provides may be different from the non-GAAP information provided by other companies.

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 21, 2004

CHOLESTECH CORPORATION

By: /s/ William W. Burke

---

William W. Burke  
Vice President of Finance, Chief  
Financial Officer, Treasurer and  
Secretary

**Table of Contents**

**Index to Exhibits**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release of Cholestech Corporation dated April 21, 2004